Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Isoxsuprine, nifedipine similarly effective in preventing preterm birth

Elaine Soliven
13 Apr 2018

Treatment with the tocolytic agents isoxsuprine or nifedipine was similarly effective in delaying delivery by 2 weeks among women who were admitted for preterm labour, according to a study presented at the RCOG World Congress 2018.

“The ideal tocolytic agent should be myometrium-specific, easy to administer, inexpensive, effective in preventing preterm birth, and improve neonatal outcomes, with few maternal, foetal, and neonatal side effects,” said lead author Dr Dhanielle E. Garcia-Ramos from the Department of Obstetrics and Gynecology at Far Eastern University – Dr Nicanor Reyes Medical Foundation, Quezon City, Philippines.

“The World Health Organization also stated that three-quarters of neonates born prematurely could be saved with current, cost-effective interventions, even without intensive care facilities,” Garcia-Ramos added.

The researchers retrospectively analysed 206 women (mean age 29 years) presenting with preterm labour (defined as labour occurring between 28 and 36 weeks of gestation) who were given isoxsuprine (n=142) or nifedipine (n=64). Majority of the participants were admitted to the hospital during their 32nd week of pregnancy. [RCOG 2018, abstract 5638]

Both nifedipine and isoxsuprine extended pregnancy by 2 weeks in average (range 0–7 weeks), and there was no significant difference between the two treatment groups (mean gestational age at delivery, 34.8 vs 34.9 weeks; p=0.67).

“Both nifedipine and isoxsuprine were comparable in reducing the risk of delivery within 48 hours from initiation of treatment and before 37 weeks age of gestation. The delay in delivery has led to significant improvements in clinically important neonatal outcomes such as the Apgar and Ballard’s score for both agents,” Garcia-Ramos said.

The researchers found no significant difference in the Apgar scores for 1 minute (8.6 vs 8.6; p=0.84) and 5 minutes (9.7 vs 9.7; p=0.75), which were usually expected from neonates born at >34 weeks. Ballard’s score (35.2 vs 35.5 weeks; p=0.32) and birthweight (2,212.6 vs 2,159.8 grams; p=0.49) were also similar between the infants whose mothers were treated with isoxsuprine vs with nifedipine.

Neonatal morbidities were higher among infants whose mothers received nifedipine vs isoxsuprine (14.1 percent vs 9.8 percent), although the difference was not statistically significant.

“We noted the associated morbidities with prematurity such as sepsis, neonatal pneumonia, and transient tachypnoea of the newborn to occur among the neonates of the cases who delivered at 33 weeks and below,” said the researchers.

However, a significantly higher incidence of tachycardia was observed in women treated with isoxsuprine vs nifedipine (10 percent vs 0 percent; p=0.03). “With regards to adverse effects, nifedipine was found to be a favourable choice ... Thus, we can report that nifedipine can be better tolerated than isoxsuprine,” noted Garcia-Ramos.

“Nifedipine is equally efficacious as isoxsuprine in preventing preterm birth with better maternal tolerability. Therefore, this may result in better compliance to tocolytic therapy which can contribute to a successful outcome,” Garcia-Ramos added, who suggested that future research should include women with comorbidities, and those at higher risk of preterm labour such as those diagnosed with multiple gestations and premature rupture of membranes.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.